← Back to Search

Norepinephrine Precursor

Treatment group for Parkinson's Disease

Phase 2
Waitlist Available
Led By Abraham Lieberman, MD
Research Sponsored by St. Joseph's Hospital and Medical Center, Phoenix
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up study weeks 2, 4 and 8
Awards & highlights

Study Summary

This study is evaluating whether a medication may help individuals with major depressive disorder.

Eligible Conditions
  • Patient Falls
  • Parkinson's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~study weeks 2, 4 and 8
This trial's timeline: 3 weeks for screening, Varies for treatment, and study weeks 2, 4 and 8 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in number of falls
Secondary outcome measures
Change in objective and subjective measures of Balance

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Treatment groupExperimental Treatment2 Interventions
This group will receive droxidopa 100mg to 600mg three times a day (TID) titration for 2 weeks and then maintenance dosage for 4 additional weeks. We will assess participants two times over the 4-week intervention. Each assessment will be the same as the baseline assessment, including the Orthostatic Hypotension Symptom Assessment (OHSA), postural, and gait assessments, and will be administered during the 2nd and 4th weeks following onset of stable treatment phase.
Group II: Non treatment groupPlacebo Group1 Intervention
This group will receive placebo appearing to be 100mg to 600mg three times a day (TID) titration for 2 weeks and then maintenance dosage for 4 additional weeks. We will assess participants two times over the 4-week intervention. Each assessment will be the same as the baseline assessment, including the Orthostatic Hypotension Symptom Assessment (OHSA), postural, and gait assessments, and will be administered during the 2nd and 4th weeks following onset of stable treatment phase.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Droxidopa
FDA approved

Find a Location

Who is running the clinical trial?

St. Joseph's Hospital and Medical Center, PhoenixLead Sponsor
63 Previous Clinical Trials
14,607 Total Patients Enrolled
H. Lundbeck A/SIndustry Sponsor
325 Previous Clinical Trials
77,571 Total Patients Enrolled
Arizona State UniversityOTHER
283 Previous Clinical Trials
109,504 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH)
2018. "Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03567447.
All > Orthostatic Hypotension
~1 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top